More than 2.5 billion doses have been ordered worldwide of the Oxford-AstraZeneca vaccine, providing a ray of hope in the fight against the pandemic.
Experts from across The Conversation assess the work that's helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
The reason the vaccine appears to have worked better in participants who initially received only half a dose is still somewhat of a mystery.
We need more data on the low-dose, high-dose regimen used in one arm of the trial, which may make the vaccine more effective.
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
With COVID-19 vaccine announcements making headlines, non-scientists need to know what clinical trial results mean. Here are some key points to look for in vaccine trial reports.
There is now a third vaccine that prevents COVID-19 infections. It isn't quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Amid good news on the vaccine trial-front, Australia must think more carefully about how a national roll-out would work.
Data coming through from phase 3 trials are encouraging. But participants don't represent the whole community — so we can't be sure these vaccines will work as well in everyone.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Promising vaccines such as Pfizer's will play a role in ending the pandemic – but widespread immunity isn't yet on the horizon.
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here's where we stand on vaccine development, including positive results from Pfizer's trial.
The government has secured deals for two further COVID-19 vaccines, taking its portfolio of agreements to four.
Experts from across The Conversation look at how COVID-19 vaccines will work, how they're being tested and manufactured, and what challenges there will be to rolling them out.
Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines' development time.
With Donald Trump already doing a great job of making the public more wary of a coronavirus vaccine, big pharma has to do better than this.
Stoppages of clinical trials are a normal part of the testing process, and show that patient safety is being taken seriously.
The phase 3 trials of the University of Oxford/AstraZeneca vaccine have been paused because one participant became unwell. But we don't know for sure if the illness was a reaction to the vaccine.